Novel therapies for proliferative retinopathies

Area of Science:

• Ophthalmology
• Angiogenesis Research
• Pharmacology

Background:

• Proliferative retinopathies cause irreversible blindness.
• These conditions involve detrimental angiogenesis driven by vascular endothelial growth factor (VEGF).
• Current treatments focus on inhibiting VEGF, but patient response varies.

Purpose of the Study:

• To describe the mechanisms of ocular antiangiogenic therapies in clinical development.
• To categorize these therapies based on their targets and mechanisms.
• To highlight potential alternative treatments for non-responsive patients.

Main Methods:

• Review of ocular antiangiogenic therapies in clinical development.
• Classification of therapies into anti-VEGF systems, non-VEGF pathway targets, and gene therapies.
• Analysis of the mechanisms of action for each category.

Main Results:

• Most therapies aim to neutralize VEGF.
• A significant number of products with diverse mechanisms are under development.
• Non-VEGF targeted therapies offer alternatives for patients resistant to anti-VEGF treatments.
• Gene therapy presents a promising but not yet fully validated approach.

Conclusions:

• Ocular antiangiogenic therapies are crucial for treating proliferative retinopathies.
• Diverse therapeutic strategies are emerging beyond simple anti-VEGF approaches.
• Targeting non-VEGF pathways and gene therapy hold potential for future treatment paradigms.